Related Experiment Videos
[A role for reactive oxygen species in the pathogenesis of focal glomerulosclerosis]
1Department of Internal Medicine (II), Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Previous studies have indicated that reactive oxygen species play a key role in puromycin aminonucleoside (PAN)-induced proteinuria in the acute nephrotic phase, and glomerular infiltration of macrophages (M phi) in the acute phase has a critical impact on the subsequent progression to glomerular sclerosis. In the present study, we examined the effect of deferoxamine (DFO), which is known to inhibit the generation of hydroxyl radical on the proteinuria, renal function and morphological changes in PAN-induced chronic glomerulopathy. Rats given a single dose of PAN (150 mg/kg BW, i.p.) were not treated (Group 1, n = 12) or treated with DFO (Group 2 and 3). In Group 2 rats (n = 12), 30 mg of DFO was given for 12 weeks after PAN injection (every day for the first 2 weeks, 3 times a week for the following 2 weeks, once a week for the last 8 weeks). In Group 3 rats (n = 14), DFO was given in an identical manner with Group 2 until 2nd week and was discontinued thereafter. 24-hour urinary protein excretion (UprV) was measured at 1st, 2nd, 4th, 8th, 12th, and 24th weeks. The percentage of segmentally sclerosed glomeruli (%SS), creatinine clearance (Ccr), and serum malondialdehyde levels (MDA) were determined at the 24th week. The average number of M phi per glomerulus (# M phi) was determined at the 4th, 8th and 24th weeks after PAN injection, by biopsy and autopsy. Compared to Group 1 rats, Group 2 rats had a significantly lower amount of UprV throughout the period with marked attenuation in %SS and Ccr. In contrast, UprV in Group 3 was comparable to that in Group 1 except for the 2nd week, and there was no significant difference in %SS or Ccr between Group 1 and 3. Of note, # M phi at 4th week, which significantly correlated with %SS, substantially decreased in Group 2 compared to Group 1 or Group 3 (p < 0.05). These data suggest that the oxidant stress persisting from the acute to the chronic phase of PAN nephropathy plays an important role in inducing glomerular sclerosis. The prevention of progressive glomerular sclerosis following DFO therapy might be associated with an improvement in early glomerular in filtration of M phi.
Insights
Deferoxamine (DFO) treatment significantly reduced proteinuria and glomerular sclerosis in rats with chronic kidney disease induced by puromycin aminonucleoside (PAN). DFO
Area of Science:
- Nephrology
- Oxidative Stress Research
- Pharmacology
Context:
- Puromycin aminonucleoside (PAN)-induced nephropathy involves reactive oxygen species and macrophage infiltration.
- Glomerular sclerosis progression is linked to acute-phase macrophage infiltration.
- Deferoxamine (DFO) inhibits hydroxyl radical generation.
Purpose:
- To investigate the efficacy of deferoxamine (DFO) in mitigating proteinuria, renal dysfunction, and morphological changes in chronic PAN-induced glomerulopathy.
- To assess the impact of DFO on oxidative stress markers and macrophage infiltration in the chronic phase of PAN nephropathy.
Summary:
- Rats treated with DFO throughout the study exhibited significantly reduced 24-hour urinary protein excretion (UprV), attenuated segmental sclerosis (%SS), and improved creatinine clearance (Ccr) compared to controls.
- DFO treatment also led to a substantial decrease in glomerular macrophage infiltration (# M phi) at week 4, which correlated with reduced %SS.
- Discontinuing DFO treatment after 2 weeks (Group 3) did not prevent the progression of glomerular sclerosis, indicating the importance of sustained DFO administration.
Impact:
- These findings highlight the critical role of persistent oxidant stress in the progression of glomerular sclerosis in PAN nephropathy.
- DFO therapy may prevent progressive glomerular sclerosis by modulating early macrophage infiltration into glomeruli.
- This study suggests a potential therapeutic strategy targeting oxidative stress and inflammation in chronic kidney disease.